VBI Vaccines, Inc. - Ordinary Shares (VBIV)
VBIV moved a median of -0.01% 30 minutes after news, and -1.49% by the close. How VBIV actually reacts to news — the realized, point-in-time move the market made, measured across 52 labeled events over the last three years with zero look-ahead.
VBIV’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.22% | 54% | 52 |
| 30-min | -0.01% | 40% | 52 |
| 60-min | -1.21% | 33% | 52 |
| to close | -1.49% | 46% | 52 |
| Middle 50% of VBIV reactions | -3.44% to +0.92% |
|---|---|
| Median reaction (30-min) | -0.01% |
| Measured reactions | 52 |
Half of all VBI Vaccines, Inc. - Ordinary Shares news events land between -3.44% and +0.92% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when VBIV moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to VBIV's baseline. Nothing else.
Recent VBIV events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K VBI Vaccines Inc/BC For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -12.50% | -21.38% | |
| VBI Vaccines Provides an Update on its Restructuring Proceedings | Press release | Business Wire | -12.50% | -21.38% | |
| Form 8-K VBI Vaccines Inc/BC For: Jul 29 | SEC filing · Form 8-K | SEC EDGAR | +13.18% | -39.48% | |
| VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives | Press release | Business Wire | +8.67% | -43.69% | |
| Form 8-K VBI Vaccines Inc/BC For: Jun 25 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.54% | |
| VBI Vaccines Announces Results of Annual General Meeting | Press release | Business Wire | +0.00% | -1.54% | |
| Form 8-K VBI Vaccines Inc/BC For: May 29 | SEC filing · Form 8-K | SEC EDGAR | -1.58% | -9.43% | |
| VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients | Press release | Business Wire | -1.58% | -9.43% | |
| Form 8-K VBI Vaccines Inc/BC For: May 24 | SEC filing · Form 8-K | SEC EDGAR | +1.52% | -1.54% | |
| VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients | Press release | Business Wire | +0.00% | -1.45% | |
| Form 10-Q VBI Vaccines Inc/BC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.42% | +0.35% | |
| Form 8-K VBI Vaccines Inc/BC For: May 09 | SEC filing · Form 8-K | SEC EDGAR | +0.42% | +0.35% | |
| VBI Vaccines Reports First Quarter 2024 Financial Results | Press release | Business Wire | +0.42% | +0.35% | |
| Form 8-K VBI Vaccines Inc/BC For: Apr 30 | SEC filing · Form 8-K | SEC EDGAR | -0.36% | +3.67% | |
| Form ARS VBI Vaccines Inc/BC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.18% | +4.37% | |
| Form DEF 14A VBI Vaccines Inc/BC For: Apr 29 | SEC filing · Form DEF | SEC EDGAR | +1.18% | +4.37% | |
| Form DEFA14A VBI Vaccines Inc/BC | SEC filing · Form DEFA14A | SEC EDGAR | +1.18% | +4.37% | |
| Form 10-K VBI Vaccines Inc/BC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.35% | +10.71% | |
| Form 8-K VBI Vaccines Inc/BC For: Apr 16 | SEC filing · Form 8-K | SEC EDGAR | +1.35% | +10.71% | |
| VBI Vaccines Reports Full Year 2023 Financial Results | Press release | Business Wire | +1.35% | +10.71% | |
| Form 8-K VBI Vaccines Inc/BC For: Apr 09 | SEC filing · Form 8-K | SEC EDGAR | +2.71% | -2.34% | |
| VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Press release | Business Wire | +2.71% | -2.34% | |
| VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | Press release | Business Wire | -5.53% | -25.17% | |
| Form 8-K VBI Vaccines Inc/BC For: Apr 03 | SEC filing · Form 8-K | SEC EDGAR | +0.14% | +6.56% | |
| VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma | Press release | Business Wire | +0.14% | +6.56% | |
| Form 8-K VBI Vaccines Inc/BC For: Apr 02 | SEC filing · Form 8-K | SEC EDGAR | -2.08% | +8.80% | |
| VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform | Press release | Business Wire | -2.08% | +8.80% | |
| Form NT 10-K VBI Vaccines Inc/BC For: Dec 31 | SEC filing · Form NT | SEC EDGAR | -0.10% | +3.02% | |
| Form 8-K VBI Vaccines Inc/BC For: Feb 14 | SEC filing · Form 8-K | SEC EDGAR | -5.62% | -20.06% | |
| VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences | Press release | Business Wire | -5.62% | -20.06% | |
| Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies | Press release | PR Newswire | -5.62% | -20.06% | |
| Form 8-K VBI Vaccines Inc/BC For: Feb 06 | SEC filing · Form 8-K | SEC EDGAR | +3.95% | +3.06% | |
| Form 8-K VBI Vaccines Inc/BC For: Jan 23 | SEC filing · Form 8-K | SEC EDGAR | -0.59% | +1.15% | |
| Form 8-K VBI Vaccines Inc/BC For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.60% | |
| Form 8-K VBI Vaccines Inc/BC For: Dec 26 | SEC filing · Form 8-K | SEC EDGAR | +3.33% | -4.67% | |
| Form 8-K VBI Vaccines Inc/BC For: Dec 12 | SEC filing · Form 8-K | SEC EDGAR | -1.41% | -8.03% | |
| Form 8-K VBI Vaccines Inc/BC For: Nov 28 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +0.85% | |
| Form 8-K VBI Vaccines Inc/BC For: Nov 20 | SEC filing · Form 8-K | SEC EDGAR | +3.30% | +15.00% | |
| VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting | Press release | Business Wire | +3.30% | +15.00% | |
| Form 10-Q VBI Vaccines Inc/BC For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.30% | -5.18% | |
| Form 8-K VBI Vaccines Inc/BC For: Nov 14 | SEC filing · Form 8-K | SEC EDGAR | +0.30% | -5.18% | |
| VBI Vaccines Reports Third Quarter 2023 Financial Results | Press release | Business Wire | +0.30% | -5.18% | |
| Form 8-K VBI Vaccines Inc/BC For: Nov 01 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -1.62% | |
| Form 8-K VBI Vaccines Inc/BC For: Oct 26 | SEC filing · Form 8-K | SEC EDGAR | -2.00% | +20.80% | |
| VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program | Press release | Business Wire | -2.00% | +20.80% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the VBIV section they belong to.
Where else VBIV is measured.
VBIV earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| UNITED HEALTH PRODUTS INC (UEEC) | 53 | 0.00% | 43% |
| EASTON PHARMS INC (EAPH) | 52 | 0.00% | 34% |
| Crescent Biopharma, Inc. (CBIO) | 51 | -1.24% | 50% |
| Careview Communications, Inc. (CRVW) | 51 | 0.00% | 12% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is VBI Vaccines, Inc. - Ordinary Shares's median reaction calculated?
Every labeled VBIV news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 52 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 40% of VBIV's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does VBIV's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.